Abstract
Diosmetin (Dios), a flavone aglycone, is a major active ingredient of many herbal medicines. Previous studies implicated that the potential antitumor activities of Dios are mediated through multiple cell signaling pathways, however more investigations are required to reveal the targets and mechanisms of Dios. In this study, our results demonstrated that cell cycle progression and proliferation of HepG2 cells were inhibited by Dios. Meanwhile, Dios-induced liver cancer cell apoptosis was related with the p53 activation. After PFT-α, a p53 inhibitor was added into Dios-treated HepG2 cells, cell growth inhibition was partially reversed. These findings defined and supported that p53 is a novel target of Dios. By activating p53, Dios exerts anticancer effects by inducing cell cycle arrest and apoptosis in HepG2 cells.
Keywords: Diosmetin, HepG2, P53, apoptosis, flavonoids, ERK and JNK phosphorylation.
Protein & Peptide Letters
Title:Diosmetin, a Potential p53 Activator, Performs Anticancer Effect by Regulating Cell Cycling and Cell Proliferation in HepG2 Cells
Volume: 24 Issue: 5
Author(s): Bin Liu*, Miaomiao Zhang, Shuna Liu, Jie Ying, Jingjing Zhang, Hiroshi Kurihara, Weiqiang Zheng, Rong-Rong He*Runzhi Zhu
Affiliation:
- Infection department of Internal Medicine, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, Guangdong Province,China
- College of Pharmacy, Jinan University, Guangzhou 510632, Guangdong Province,China
Keywords: Diosmetin, HepG2, P53, apoptosis, flavonoids, ERK and JNK phosphorylation.
Abstract: Diosmetin (Dios), a flavone aglycone, is a major active ingredient of many herbal medicines. Previous studies implicated that the potential antitumor activities of Dios are mediated through multiple cell signaling pathways, however more investigations are required to reveal the targets and mechanisms of Dios. In this study, our results demonstrated that cell cycle progression and proliferation of HepG2 cells were inhibited by Dios. Meanwhile, Dios-induced liver cancer cell apoptosis was related with the p53 activation. After PFT-α, a p53 inhibitor was added into Dios-treated HepG2 cells, cell growth inhibition was partially reversed. These findings defined and supported that p53 is a novel target of Dios. By activating p53, Dios exerts anticancer effects by inducing cell cycle arrest and apoptosis in HepG2 cells.
Export Options
About this article
Cite this article as:
Liu Bin*, Zhang Miaomiao, Liu Shuna, Ying Jie, Zhang Jingjing, Kurihara Hiroshi, Zheng Weiqiang, He Rong-Rong*, Zhu Runzhi, Diosmetin, a Potential p53 Activator, Performs Anticancer Effect by Regulating Cell Cycling and Cell Proliferation in HepG2 Cells, Protein & Peptide Letters 2017; 24 (5) . https://dx.doi.org/10.2174/0929866524666170223094634
DOI https://dx.doi.org/10.2174/0929866524666170223094634 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Naphthoflavones as Antiproliferative Agents: Design, Synthesis and Biological Evaluation
Anti-Cancer Agents in Medicinal Chemistry Biodistribution and Pharmacokinetics of I-131 Labelled 4- Iodophenylacetic Acid
Current Radiopharmaceuticals Receptor Tyrosine Kinase Kit and Gastrointestinal Stromal Tumours: An Overview
Current Medicinal Chemistry OPLS-DA as a Suitable Method for Selecting a Set of Gene Transcripts Discriminating RAS- and PTPN11-Mutated Cells in Acute Lymphoblastic Leukaemia
Combinatorial Chemistry & High Throughput Screening Concise Synthesis of Benzoindolizidine Derivatives and Bioactivity Evaluation
Letters in Organic Chemistry Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs
Current Drug Metabolism Tumor Targeted Therapies: Strategies for Killing Cancer but not Normal Cells
Current Cancer Therapy Reviews Small Molecules in Cancer Therapy: Cytotoxics and Molecularly Targeted Agents
Current Signal Transduction Therapy Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Studies on Coumarins and Coumarin-Related Compounds to Determine their Therapeutic Role in the Treatment of Cancer
Current Pharmaceutical Design Determinants of Treatment Outcomes for Hepatitis C Infection and the Path to Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Antioxidant Potential of Solvent Partitioned Extraction from Aqueous Extract of Gracilaria Tenuistipitata
Current Organic Chemistry Human Carbonyl Reductases
Current Drug Metabolism ADAM28 as a Target for Human Cancers
Current Pharmaceutical Design Recombinant Snake Venom Cystatin Inhibits Tumor Angiogenesis in vitro and in vivo Associated with Downregulation of VEGF-A165, Flt-1 and bFGF
Anti-Cancer Agents in Medicinal Chemistry Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design